Multidisciplinary Treatment of Primary Melanoma
Surgical Clinics of North America, ISSN: 0039-6109, Vol: 89, Issue: 1, Page: 267-281
2009
- 10Citations
- 42Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes10
- 10
- CrossRef4
- Captures42
- Readers42
- 42
Review Description
This article covers the multidisciplinary treatment of primary melanoma. Excision margins and the need for sentinel lymphadenectomy are mainly dictated by the Breslow thickness although exceptions to this dictum do exist. Interferon is the only FDA approved adjuvant therapy for high risk melanoma although its overall survival benefit is minimal. Trials examining different doses or duration of interferon therapy have not demonstrated any promising survival data so far. There have been several randomized vaccine trials for melanoma but none have shown an overall survival benefit. Research into T-cell regulation continues and will hopefully bring promise for the future of melanoma treatment.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0039610908001837; http://dx.doi.org/10.1016/j.suc.2008.11.002; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=58749097828&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/19186240; https://linkinghub.elsevier.com/retrieve/pii/S0039610908001837; https://dx.doi.org/10.1016/j.suc.2008.11.002
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know